Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update

Oncology (Switzerland)

Volumn 87, Issue , 2014, Pages 22-31

  Kudo, Masatoshi ^a   Matsui, Osamu ^b   Izumi, Namiki ^c   Kadoya, Masumi ^d   Okusaka, Takuji ^e   Miyayama, Shiro ^f   Yamakado, Koichiro ^g   Tsuchiya, Kaoru ^c   Ueshima, Kazuomi ^a   Hiraoka, Atsushi ^h   Ikeda, Masafumi ⁱ   Ogasawara, Sadahisa ^j   Yamashita, Tatsuya ^k   Minami, Tetsuya ^k  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c MUSASHINO RED CROSS HOSPITAL   (Japan)

^d SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^g MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^j CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k KANAZAWA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Criteria of transarterial chemoembolization failure; Hepatocellular carcinoma; Transarterial chemoembolization

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; GELATIN SPONGE; IODINATED POPPYSEED OIL; MICROSPHERE; MIRIPLATIN; MITOMYCIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; ETHIODIZED OIL; NICOTINAMIDE; SORAFENIB; TUMOR MARKER;

CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSENSUS; HUMAN; JAPAN; LIVER CELL CARCINOMA; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; HEALTH CARE SURVEY; HEPATIC ARTERY; LIVER FUNCTION TEST; LIVER NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; HEALTH CARE SURVEYS; HEPATIC ARTERY; HUMANS; JAPAN; LIVER FUNCTION TESTS; LIVER NEOPLASMS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84922480804     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000368142     Document Type: Conference Paper

References (13)

1. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50.
2. Minami Y, Yagyu Y, Murakami T, et al: Tracking navigation imaging of transcatheter arterial chemoembolization for hepatocellular carcinoma using three-dimensional conebeam CT angiography. Liver Cancer 2014; 3: 53-61.
3. Raoul JL, Gilabert M, Piana G: How to define transarterial chemoembolization failure or refractoriness: A European perspective. Liver Cancer 2014; 3: 119-124.
4. Kudo M, Izumi N, Kokudo N, et al: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
5. Park JW, Amarapurkar D, Chao Y, et al: Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int 2013; 33: 327-337.
6. Sieghart W, Hucke F, Pinter M, et al: The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013; 57: 2261-2273.
7. Kudo M, Arizumi T, Ueshima K: Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2014; 59: 2424-2425.
8. Kadalayil L, Benini R, Pallan L, et al: A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013; 24: 2565-2570.
9. Kudo M: Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. Liver Cancer 2012; 1: 141-143.
10. Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012; 1: 2-14.
11. Kudo M, Matsui O, Izumi N, et al: JSH consensus-based clinical practice guideline for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-468.
12. Yamakado K, Miyayama S, Hirota S, et al: Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014; 32: 260-265.
13. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012; 1: 62-70.